Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Results from the BEATcc study strongly support the use of first-line combination therapy for R/M CC in all patients
The TROP2-directed ADC improved PFS with reduced toxicity compared with chemotherapy in the TROPION-Lung01 trial, but results are not practice-changing
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time
In the NICHE-3 study, all patients achieved a pathological response
Negative trials presented at the ESMO Congress 2023 suggest that a new treatment strategy may be required for patients with metastatic disease
Results from four early-phase studies show that combining immune checkpoint inhibitors with other immunotherapies or with TKIs is a potentially efficacious strategy for the treatment of different diseases including GIST and vascular sarcomas
Safety and efficacy data of some novel immunotherapy agents are encouraging, but more research is needed to identify biomarkers and the optimal treatment schedule
Data from selected patients in the RUBY trial show improvements in QoL domains over the course of treatment and benefits compared with placebo
Results from studies presented at the ESMO Congress 2023 (Madrid, 20–24 October) outline different strategies involving indirect immune modulation and direct enhanced tumour cytotoxicity to improve on chemotherapy as the current standard of second-line care after ICI progression
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.